Search the Newsreel

Sellas Life Sciences: Options Traders Pile In as a Leukemia Trial Reaches Its Defining Threshold

Options traders are heavily investing in Sellas Life Sciences as its pivotal Phase 3 REGAL trial for acute myeloid leukemia reached the 80 pre-specified death events required for final efficacy analysis, with overall survival data expected in Q4. The stock surge was also influenced …

SELLAS Shares Gain $416 Million With REGAL Trial Approaching Final Analysis

SELLAS Life Sciences Group (NASDAQ:SLS) saw its shares jump 15.4% on Friday, adding approximately $416 million to its market capitalization, bringing its valuation to $3.12 billion. This surge occurred without any new company announcements, suggesting investor anticipation ahead of the final analysis of its …

Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative?

SELLAS Life Sciences (SLS) reported increased net losses but improved basic loss per share in Q2 2026, alongside growing investor interest in cancer vaccines following positive news from larger peers. While the company's immunotherapy platform and promising trial data are attracting attention, its reliance …

SELLAS Life Sciences Group (SLS) Shares Just Moved, So What Is Drawing Attention?

SELLAS Life Sciences Group (SLS) Stock Looks Stretched Despite Key AML Trial Progress

SELLAS Life Sciences Group (SLS) stock has seen a significant 7.9x return over the last three years, but current valuations suggest it is expensive. Despite progress in its REGAL AML trial and SLS009 cancer indications, the stock's price-to-book ratio is much higher than industry …

SELLAS Life Sciences Group (SLS) Nears Key Phase 3 Readout On A Pricey Valuation

SELLAS Life Sciences Group (SLS) is approaching a key Phase 3 readout for its acute myeloid leukemia therapy, Galinpepimut S, attracting increased institutional interest and significant share price momentum. Despite this positive sentiment and strong stock performance, the company's valuation, with a Price-to-Book multiple …

SELLAS (SLS) Earnings Recap: EPS Misses Its Estimate in the Reported Period; Trading Response: Shares Move Higher 0.77% for the Current Session - Return On Assets

SELLAS (SLS) Q1 2026 Results: The Bottom-Line Figure Trails Its Comparison in Latest Trading; Reaction Snapshot: Shares Move Higher 1.08% - Revenue Warning Signal

Why SELLAS (SLS) Posted a Wider Net Loss but a Narrower Per-Share Loss This Quarter

SELLAS Life Sciences Group (SLS) reported a wider net loss in Q2 2026 but a narrower loss per share, driven by increasing expenses related to late-stage oncology programs. The company's investment narrative continues to revolve around the success of its Phase 3 REGAL trial …

Investors Buy High Volume of SELLAS Life Sciences Group Put Options (NASDAQ:SLS)

Traders have shown unusual bearish activity towards SELLAS Life Sciences Group (NASDAQ:SLS), purchasing 61,072 put options, which is 65% above its average daily volume. Despite this, analysts have a mixed view, with an average "Hold" rating and a $10.00 price target, while the company …

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Time to Buy?

SELLAS Life Sciences Group, Inc. (SLS) stock price, news, quote and history

SELLAS Life Sciences Group, Inc. (SLS) stock price increased by 6.15%, trading at 11.73 USD. The company is a late-stage clinical biopharmaceutical firm developing novel cancer therapeutics, with lead candidates including galinpepimut-S (GPS) and SLS009 (tambiciclib). SELLAS has strategic collaborations with Merck & Co., …

SELLAS Life Sciences Group, Inc. $SLS is Dagco Inc.'s 10th Largest Position

Dagco Inc. has significantly increased its stake in SELLAS Life Sciences Group (NASDAQ:SLS), making it their 10th largest position. Despite this institutional confidence, analyst ratings are mixed, leading to a consensus "Hold" rating, and the company recently missed its quarterly earnings estimates.

Why Is SELLAS Life Sciences Group (SLS) Getting Fresh Attention?

Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, vs. FactSet Est of $0.05 Loss

SELLAS Life Sciences Group (NASDAQ:SLS) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) announced its quarterly earnings, reporting a loss of $0.05 per share, missing analyst expectations by $0.01. Despite the earnings miss, SLS shares rose 0.1% to $11.05, with a mixed analyst sentiment leading to an overall "Hold" rating and a …

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SELLAS Life Sciences Group, Inc. reported its second-quarter 2026 financial results, highlighting progress in its lead clinical programs, GPS and SLS009. The company is nearing the final efficacy analysis for the Phase 3 REGAL trial of GPS in AML and expects topline data for …

Sellas Life Sciences reports wider loss as REGAL trial nears final analysis (SLS:NASDAQ)

SELLAS Life Sciences Group, Inc. Q2 2026: Revenue $0 Net loss $(9.6M), EPS $(0.05) — 10-Q Summary

SELLAS Life Sciences Group, Inc. reported its second-quarter 2026 results, showing no revenue and a net loss of $(9.6M), or $(0.05) diluted loss per share. This represents a worsening net loss compared to the $(6.6M) in the prior-year quarter, though diluted EPS improved from …

SELLAS Life Sciences (SLS) Q1 2026 Earnings: Net Loss Misses Estimates as Clinical-Stage Investment Continues - Guidance Revision Trend

SELLAS Life Sciences Group (SLS) Earnings Date and Reports 2026 $SLS

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.8% - What's Next?

Sellas Life Sciences Group Stock (SLS) Opinions on Institutional Buying Surge

The article discusses the recent surge in institutional buying of Sellas Life Sciences Group (SLS) stock, noting a significant increase in the number of funds and shares held by institutions. Despite this, the stock's price performance has been negative over various periods, underperforming the …

State Street Corporation (SLS) discloses 7% ownership of SELLAS Life Sciences common stock

State Street Corporation and its investment adviser subsidiaries have reported a 7% passive ownership stake in SELLAS Life Sciences Group Inc., as detailed in a Schedule 13G filing. As of June 30, 2026, they beneficially owned 12,996,558 shares, exercising shared voting and dispositive power …

Sellas Life Sciences may see 12% move on Aug. 13 earnings

Sellas Life Sciences Group Inc. is projected to experience a 12% stock movement when it reports earnings on August 13, according to options data. This prediction, derived from options trading, has accurately indicated the direction of stock price movements in six out of its …

SELLAS Life Sciences Group, Inc. (RXK3.F) Stock Price, News, Quote & History

This article provides detailed financial information, news, and historical data for SELLAS Life Sciences Group, Inc. (RXK3.F). It covers the company's stock performance, key financial metrics, an overview of its biopharmaceutical operations, and recent clinical development collaborations. The data highlights significant stock returns over …

SELLAS Life Sciences Group (SLS) Is Up 11.2% After Daiwa Boosts Stake And REGAL Nears Readout - Has The Bull Case Changed?

SELLAS Life Sciences Group (SLS) shares rose 11.2% following Daiwa Securities' increased stake and the imminent readout of the Phase 3 REGAL trial for acute myeloid leukemia. With 78 out of 80 events reached for final analysis and a strong cash position of US$138.30 …

SELLAS Life Sciences Group (SLS) Nears REGAL Analysis, Is The Stock Too Expensive?

SELLAS Life Sciences Group (SLS) is approaching the final analysis of its Phase 3 REGAL trial for acute myeloid leukemia, coinciding with a significant increase in shareholding by Daiwa Securities. Despite a recent surge in stock price, including a 157.93% year-to-date return, the company's …

SELLAS Life Sciences Group (SLS) Stock Looks Priced At A Premium

SLS Stock Climbs Premarket: Here’s What Smart Money Is Doing As Sellas Nears Critical Phase 3 AML Readout

Sellas Life Sciences (SLS) stock saw premarket gains as investors reacted to mixed institutional stake disclosures and the company's nearing Phase 3 clinical trial readout for its AML drug. CEO Angelos Stergiou highlighted the role of AI in drug development and patient selection, while …

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 12.4% Higher - Time to Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) saw its shares rise by 12.4% on Monday, trading at $11.25 with 4.46 million shares exchanged, which is 47% below its average daily volume. Analyst sentiment is mixed, with a "Hold" consensus and an average price target of $10.00. …

SELLAS Life Sciences Group Stock (SLS) Opinions on Clinical Trial Catalysts

Social media discussions highlight an anticipated surge in SELLAS Life Sciences Group (SLS) stock due to upcoming clinical data releases and potential acquisition rumors. Analysts suggest price targets of $25 to $30 in a successful trial scenario, with market sentiment shifting to cautiously positive …

SELLAS Life Sciences Group (SLS) Expected to Release Quarterly Earnings on Thursday